Jefferies cuts PB Fintech target 25% to Rs 1,540 on potential IRDA commission curbs

Jefferies cut PB Fintech’s valuation multiple by 30% to 18x FY30E EBITDA, citing proposed insurance commission rules that could pressure Policybazaar take rates and earnings. The brokerage sees Rs 1,620 upside and Rs 1,030 downside, while PB Fintech weighs slower spend and new monetisation levers.

— Source publishedFri, 25 Sept, 2026, 08:18 IST·First seen Fri, 25 Sept, 2026, 08:40 IST·Source Business Today · Latest

What happened

Jefferies cut PB Fintech’s target to Rs 1,540 as proposed IRDA commission rules could pressure Policybazaar take rates and earnings. PB plans slower hiring and

Key facts

  • Jefferies cut PB Fintech's valuation multiple by 30% to 18x estimated FY30 EBITDA
  • Target price cut to Rs 1,540
  • Base-case revenue CAGR: 31% for FY26-FY29
  • Upside target: Rs 1,620
  • Downside target: Rs 1,030
  • Proposed commission cuts could reduce non-life NPV to 33-40% of original NPV
  • A 10% cut in new-business commission rates could lower earnings by 10-12%

Why this matters

Potential regulatory pressure on commissions could make partnerships, embedded-insurance distribution and adjacent revenue streams more strategically valuable for PB Fintech.

What to watch

  • Final IRDAI wording on commission caps, effective dates, product exemptions and treatment of broker/service remuneration.
  • Management commentary on expected take-rate impact, insurer negotiations and FY27/FY28 margin targets.
  • Quarterly new premium growth, revenue yield per policy, renewal contribution and customer-acquisition cost trends.
  • Any slowdown in marketing spend or deterioration in policy issuance growth following a profitability pivot.
  • Competitor responses from insurers, aggregators and offline distributors that could alter pricing or customer acquisition economics.
  • Evidence that new monetisation streams or credit cross-sell are scaling quickly enough to offset insurance commission pressure.
  • Reduce paid acquisition intensity and shift marketing toward higher-conversion, renewal-rich cohorts.
  • Push insurer negotiations for marketing support, technology/service fees and preferential economics tied to volumes and persistency.
  • Accelerate monetisation from renewals, premium financing, lender partnerships, POSP/advisor tools and cross-sell into credit products.
  • Prioritise health, term-life and higher-ticket products where customer lifetime value can better absorb lower upfront commissions.
  • Increase focus on EBITDA and contribution-margin disclosures to defend investor confidence during regulatory uncertainty.